News

Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis
Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the ...
Mena FN1mon
Alphyn Secures FDA Clearance Of Investigational New Drug Application For Atopic Dermatitis Treatment
Feb. 19, 2025 /PRNewswire/ -- Alphyn , a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics ®, announced today that the U.S. Food and Drug Administration (FDA ...
Morningstar4d
Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis
"The initiation of patient dosing in our CLEAR-AD1 Phase 2b clinical trial is another significant milestone for Alphyn, as we strive to bring to market our single comprehensive treatment for ...